Cardiovascular • May 1-3, 2017
Boston, MA • United States

Past Forum: 2016

Summary

The 2016 World Medical Innovation Forum focused on cancer and opened with a wave of young investigators highlighting promising developments in a series of rapid-fire presentations. Recurring themes of the First Look session included the use of RNA in-situ hybridization (RNA-ISH) as a diagnostic tool, liquid biopsies for exosome analysis, and precision medicine approaches to patient care. Multiple presentations also highlighted the capabilities of the AMIGO suite at Brigham and Women’s Hospital, which uses intraoperative imaging to guide precise localization and analysis of patient tumors during surgery.

Attendees then had the chance to liaise with established Harvard Medical School faculty over lunch during the Discovery Café session, which paired interested Forum attendees with renowned leaders in their respective fields. Nearly 30 faculty members covered topics such as immunotherapy, diagnostics, therapy resistance, and the potential of CRISPR for research and therapeutics.

The Forum plenary opened with David Torchiana, MD, CEO and Anne Klibanski MD, Chief Academic Officer of Partners HealthCare, who welcomed an audience representing more than two dozen countries and introduced a program filled with high-caliber speakers and hot topics including immunotherapy, epigenetics, and bioinformatics. They emphasized the importance of collaboration to accomplish the goal of providing better care and support to cancer patients and their families and noted that the “engine of innovation is running better than ever” as we seek to push the boundaries of the many diseases collectively known as cancer.

Additional Highlights

  • Remarks from Greg Simon, Executive Director, The White House Moonshot Initiative
  • Executive Fireside Chats with health care leaders: Richard Gonzalez, CEO of AbbVie, Robert Bradway, CEO of Amgen, Giovanni Caforio, MD, CEO, Bristol-Myers Squibb, Kathy Giusti, Founder MMRF, and Joseph Jimenez, CEO, Novartis
  • War or Moonshot: Where do we stand? Nancy Snyderman, MD, Medical Advisor at GE Healthymagination, sat down with Monica Bertagnolli, MD, Chief of the Division of Surgical Oncology at Brigham and Women’s Hospital, and Daniel Haber, MD, PhD, Director of the MGH Cancer Center to discuss what’s to come in a new era of cancer research and care. Panelists were tasked with advising on whether cancer research and care over the next decade will be a war or a moonshot. They agreed on both perspectives – a war because, from a patient perspective, it is a personal battle against disease and we must come together as an army to combat the disease and work effectively towards a cure, and a moonshot because progress in cancer happens with huge steps forward and reflects the combined efforts of a large group of people working toward a common goal, much like landing on the moon.
  • Sessions moderated by leading broadcast journalists, experienced healthcare executives and venture capital leaders, including: Nancy Snyderman, MD, Medical Advisor at GE Healthymagination, CNBC Biotech and Pharma Reporter Meg Tirrell, Robert Tepper, MD of Third Rock Ventures, Sue Sigel, CEO, GE Ventures and Healthymagination, Thomas Lynch, CEO, MGPO, Sheila Dharmarajan, Head of BD, Zelnick Media Capital, Caroline Chen, Reporter, Bloomberg Business, Mallika Marshall, MD, Health Reporter, WBZ-TV/CBS Boston
  • Astellas Pharma announced the launch of the inaugural C3 Prize™

Partners HealthCare announced the Disruptive Dozen, 12 technologies predicted to have the greatest impact on cancer care in the next decade. The main stage was filled with 12 influential leaders in cancer research and clinical care from Massachusetts General Hospital, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, who came together for an exciting and insightful discussion around these state-of-the-art medical technologies and what they mean for the future of the field.

A full recap of the 2016 event is located here: worldmedicalinnovation.org/past-forums

Keynoters

Joseph Jimenez, CEO, Novartis
Joseph Jimenez

CEO, Novartis

Bradway-Bob
Robert Bradway

CEO, Amgen

Robert Mulroy
Robert Mulroy

CEO, Merrimack Pharmaceuticals

Briggs Morrison, CEO, Syndax Pharmaceuticals
Briggs Morrison, MD

CEO, Syndax Pharmaceuticals

Meeker-David
David Lee

CEO, Lumicell

Marc de Garidel
Marc de Garidel

Chairman and CEO, Ipsen

Paul Hudson, President, AstraZeneca US and Executive Vice President, North America
Paul Hudson

President, AstraZeneca US, Executive Vice President,
AstraZeneca North America

Torchiana hi_res
David Torchiana, MD

CEO, Partners HealthCare

Daniel Haber, PhD, MD
Daniel Haber MD, PhD

Director, Massachusetts General Hospital Cancer Center, Kurt J. Isselbacher / Peter D. Schwartz Professor of Oncology, Harvard Medical School

Glenn Dranoff, MD
Glenn Dranoff, MD

Global Head of Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

Chris Viehbacher
Christopher Viehbacher

Managing Partner, Gurnet Point Capital

Henri Termeer
Henri Termeer
Jean-François Formela, MD
Jean-François Formela, MD

Partner, Atlas Venture

Robert Tepper, MD
Bob Tepper, MD

Partner, Third Rock Ventures

Kathy Giusti
Kathy Giusti

Founder and Executive Chairman, MMRF

Giovanni Caforio
Giovanni Caforio, MD

CEO, Bristol-Myers Squibb

Richard Gonzalez
Richard Gonzalez

CEO, AbbVie

Michael Pellini, MD
Michael Pellini, MD

CEO, Foundation Medicine

David Schenkein, MD
David Schenkein, MD

CEO, Agios Pharmaceuticals

Bruno Strigini
Bruno Strigini

President, Novartis Oncology

William Hait
William Hait, MD, PhD

Global Head, Janssen R&D, J&J

Gary Reedy
Gary Reedy

CEO, American Cancer Society

Tom Lynch, MD
Thomas Lynch, MD

CEO, Mass General Physician’s Organization

Monica Bertagnolli, MD
Monica Bertagnolli, MD

Chief, Division of Surgical Oncology, Brigham and Women’s Hospital, Professor of Surgery, Harvard Medical School

Judy Salerno, MD
Judy Salerno, MD

CEO, Susan G. Komen for the Cure

William Sellers, MD
William Sellers, MD

Vice President and Global Head of Oncology, Novartis Institutes for BioMedical Research

nancy-snyderman
Nancy Snyderman, MD

Medical Advisor, GE Healthymagination

Amir Nashat, PhD
Amir Nashat, PhD

Managing Partner, Polaris Partners

Jim Robinson
Jim Robinson

President, Americas Operations, Astellas

Francis Cuss
Francis Cuss, MD

Executive Vice President and Chief Scientific Officer, R&D, Bristol-Myers Squibb

Panels

Day One: Monday, April 25, 2016

First Look: The Next Wave of Cancer Breakthroughs

Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare

Forum Opening and Announcements

  • Anne Klibanski, MD
    Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School
  • David Torchiana, MD
    CEO, Partners HealthCare

A War or Moonshot: Where Do We Stand?

  • Nancy Snyderman, MD
    Medical Advisor, GE Healthymagination
  • Monica Bertagnolli, MD
    Chief, Division of Surgical Oncology, BWH
    Professor of Surgery, Harvard Medical School
  • Daniel Haber, MD, PhD
    Director, MGH Cancer Center
    Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology, Harvard Medical School

Creating a Disruptive Cancer Pipeline

  • Robert Tepper, MD
    Partner, Third Rock Ventures
    Adjunct Professor, Harvard Medical School
  • James Bradner, MD
    President, Novartis Institutes for BioMedical Research
  • George Demetri, MD
    Director, Center for Sarcoma and Bone Oncology
    Senior Vice President for Experimental Therapeutics, Institute Physician, DFCI
  • Keith Flaherty, MD
    Director, Clinical Research, MGH Cancer Center
    Associate Professor of Medicine, Harvard Medical School
  • Sean Harper, MD
    Executive Vice President, Research and Development, Amgen

Curative Therapies: The Economics of Game Changing Science

  • Gregg Meyer, MD
    Chief Clinical Officer, Partners HealthCare
  • Sue Siegel, CEO
    GE Ventures and Healthymagination
  • Troyen Brennan, MD
    Executive Vice President and CMO, CVS Health
  • Paul Hudson
    President, AstraZeneca US
    Executive Vice President, AstraZeneca North America
  • Betsy Nabel, MD
    President, Brigham and Women’s Hospital
    Professor of Medicine, Harvard Medical School
  • Gary Reedy, CEO
    American Cancer Society
  • Peter Slavin, MD
    President, Massachusetts General Hospital
    Professor of Healthcare Policy, Harvard Medical School

Winning Portfolio Strategy

  • Thomas Lynch, MD
    CEO, Mass General Physician's Organization
  • Francis Cuss, MD
    Executive Vice President and Chief Scientific Officer, R&D, Bristol-Myers Squibb
  • Peter Lebowitz, MD, PhD
    Global Therapeutic Area Head, Oncology, Janssen R&D , J&J
  • Briggs Morrison, MD
    CEO, Syndax Pharmaceuticals
  • Alessandro Riva, MD
    Global Head, Oncology Development and Medical Affairs, Novartis Oncology
  • Phil Rowlands, PhD
    Interim Head, Oncology, Therapeutic Area Unit, Takeda

Early Detection and Prevention of Cancer

  • David Louis, MD
    Pathologist-in-Chief, MGH
    Benjamin Castleman Professor of Pathology, Harvard Medical School
  • Andy Chan, MD
    Program Director, Gastroenterology Training Program, MGH
    Associate Professor of Medicine, Harvard Medical School
  • William Hait, MD, PhD
    Global Head, Janssen Research & Development , J&J
  • Krishna Kumar
    CEO, Emerging Businesses, Philips
  • Massimo Loda, MD
    Senior Pathologist, Principal Investigator, BWH, DFCI
    Professor, Department of Pathology, Harvard Medical School

Innovation Break: Announcing the C³ Prize from Astellas Oncology and the World Medical Innovation Forum

Ropes & Gray Dinner Program Fireside Chat: Richard Gonzalez, CEO, AbbVie

  • Edward Lawrence
    Retired Partner, Ropes & Gray
  • Nancy Snyderman, MD
    Medical Advisor, GE Healthymagination
  • Richard Gonzalez
    CEO, AbbVie

Day Two: Tuesday, April 26, 2016

Global Cancer Markets

  • Sheila Dharmarajan
    Head of Business Development, Zelnick Media Capital
  • Newton Crenshaw
    Vice President of North America Oncology, Eli Lilly and Company
  • Marc de Garidel
    Chairman and CEO, Ipsen
  • Gillian Leng, MD
    Deputy Chief Executive, Director of Health and Social Care, National Institute for Health and Care Excellence
  • James Robinson
    President, Americas Operations, Astellas
  • Bruno Strigini
    President, Novartis Oncology

Epigenetics and Novel Cancer Targets

  • Pat Fortune, PhD
    Senior Market Sector Leader, Partners Innovation
  • Robert Copeland, PhD
    President of Research and Chief Scientific Officer, Epizyme
  • Keith Dionne, PhD
    CEO, Constellation Pharmaceuticals, Inc.
  • Cigall Kadoch, PhD
    Assistant Professor, DFCI, Harvard Medical School
  • Jeannie Lee, MD, PhD
    Professor of Genetics, MGH
  • Nancy Simonian, MD
    CEO, Syros Pharmaceuticals
  • Johnathan Whetstine, PhD
    Tepper Family MGH Research Scholar,
    Associate Professor of Medicine, Harvard Medical School

Fireside Chat: Robert Bradway, CEO, Amgen

  • Cathy Minehan
    Dean, School of Management, Simmons College
  • Caroline Chen
    Reporter, Bloomberg Business
  • Robert Bradway
    CEO, Amgen

Immunotherapy I: Checkpoint Activation and Cancer Vaccines

  • Nir Hacohen, PhD
    Immunologist, MGH Center for Immunology and Inflammatory Diseases, MGH Research Scholar, Associate Professor, Medicine, Harvard Medical School
  • Thomas Daniel, MD
    Chairman, Celgene Research
  • Glenn Dranoff, MD
    Global Head of Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research
  • Robert Mulroy
    President and CEO, Merrimack Pharmaceuticals
  • David Reese, MD
    Senior Vice President, Translational Sciences, Amgen
  • Scott Rodig, MD, PhD
    Associate Professor, BWH
  • Arlene Sharpe, MD, PhD
    Leader, Cancer Immunology, BWH, DFCI, George Fabyan Professor of Comparative Pathology, Harvard Medical School

 

Fireside Chat: Andy Slavitt, Acting Administrator, CMS

  • David Torchiana, MD
    CEO, Partners HealthCare
  • Meg Tirrell
    Biotech and Pharma Reporter, CNBC
  • Andy Slavitt
    Acting Administrator, CMS

Fireside Chat: Giovanni Caforio, MD, CEO, Bristol-Myers Squibb

  • Thomas Lynch, MD
    CEO, Mass General Physician's Organization
  • Meg Tirrell
    Biotech and Pharma Reporter, CNBC
  • Giovanni Caforio, MD
    CEO, Bristol-Myers Squibb

Fireside Chat: Patients Driving Innovation

  • Nancy Snyderman, MD
    Medical Advisor, GE Healthymagination
  • Kathy Giusti
    Founder, Multiple Myeloma Research Foundation and Multiple Myeloma Research Consortium

Immunotherapy II: Cell Based Therapies

  • David Fisher, MD, PhD
    Chief, Dermatology Service, Director, Melanoma Program, Director, Cutaneous Biology Research Center, MGH Cancer Center
    Edward Wigglesworth Professor of Dermatology, Harvard Medical School
  • Usman (Oz) Azam, MD
    Global Head, Cell & Gene Therapies Unit, Novartis
  • Mark Frohlich, MD
    Executive Vice President, Portfolio Strategy, Juno Therapeutics
  • Marcela Maus, MD, PhD
    Director of Cellular Immunotherapy, MGH, Member of the Faculty, Harvard Medical School
  • Chuck Wilson, PhD
    CEO, Unum Therapeutics

Financing Breakthrough Cancer Companies

  • Roger Kitterman
    Managing Partner, Partners Innovation Fund, Partners Innovation
  • Meg Tirrell
    Biotech and Pharma Reporter, CNBC
  • Jean-François Formela, MD
    Partner, Atlas Ventures
  • Jonathan Leff
    Partner, Deerfield Management
  • Amir Nashat, PhD
    Managing Partner, Polaris Partners
  • Christopher Viehbacher
    Managing Partner, Gurnet Point Capital

Arms Race in Radiation

  • Jonathan Behr, PhD
    Market Sector Leader, Partners Innovation
  • Jay Loeffler, MD
    Chair, Radiation Oncology, MGH
  • Daphne Haas-Kogan, MD
    Chair, Department of Radiation Oncology, BWH, DFCI
    Professor of Radiation Oncology, Harvard Medical School
  • Theodore Hong, MD
    Director, Gastrointestinal Radiation Oncology, MGH
    Associate Professor of Radiation Oncology, Harvard Medical School
  • Joseph Jachinowski
    CEO, Mevion Medical Systems
  • Dow Wilson
    CEO, Varian Medical Systems

Breakthrough Devices to Treat Cancer

  • Monica Bertagnolli, MD
    Chief, Division of Surgical Oncology, BWH
    Professor of Surgery, Harvard Medical School
  • Antonio Chiocca, MD, PhD
    Chairman, Neurosurgery, BWH
    Professor of Surgery, Harvard Medical School
  • Maurice Ferre
    MD, CEO, Insightec
  • David Lee
    CEO, Lumicell
  • Amy Pollack, MD
    Chief Medical Officer and Vice President of Global Medical Affairs for the Early Technologies Business Group/Minimally Invasive Technology Innovations (MITG), Medtronic
  • Ralph Weissleder, MD, PhD
    Director, Center for Systems Biology, MGH
    Professor, Radiology and Systems Biology, Harvard Medical School

Study Designs to Meet the Challenges of Personalized Cancer Medicine

  • Pat Fortune, PhD
    Senior Market Sector Leader, Partners Innovation
  • Gideon Gil
    Managing Editor, STAT
  • Julia Beaver, MD
    Acting Clinical Team Leader, Division of Oncology Products 1, CDER, FDA
  • Maria Koehler, MD, PhD
    Vice President, Strategy, Innovation and Collaborations, Pfizer Oncology Business Unit
  • Deborah Schrag, MD
    Chief, Division of Population Sciences, Medical Oncology, DFCI
    Professor of Medicine, Harvard Medical School
  • Mike Vasconcelles, MD
    CMO, Unum Therapeutics

Surviving Cancer: New Realities, New Needs

  • Trung Do
    Executive Director, Business Development, Partners Innovation
  • Tim Ferris, MD
    Senior Vice President of Population Health Management, PHS
  • Jani Ahonala
    CEO, Noona Healthcare
  • Don Dizon, MD
    Clinical Co-Director, Gynecologic Oncology, Founder and Director, The Oncology Sexual Health Clinic, MGH
    Associate Professor of Medicine, Harvard Medical School
  • Ann Partridge, MD
    Director, Adult Survivorship Program, Program for Young Women with Breast Cancer, DFCI
    Associate Professor of Medicine, Harvard Medical School
  • Claire Thom
    Senior Vice President, Global Oncology Development, Astellas

Wednesday, April 27, 2016

Combination Cancer Therapies: Drug Resistance and Therapeutic Index

  • Jens Eckstein, PhD
    President, SR One
  • Kenneth Anderson, MD
    Director, Jerome Lipper Multiple Myeloma Center, Kraft Family Professor of Medicine, Harvard Medical School
  • Jeffrey Engelman, MD, PhD
    Director, Thoracic Oncology and Director, Molecular Therapeutics, Medical Oncology, MGH
    Laurel Schwartz Associate Professor of Medicine, Harvard Medical School
  • Jamie Freedman, MD, PhD
    Senior Vice President, Global Clinical Development, Medimmune
  • David Schenkein, MD
    CEO, Agios Pharmaceuticals
  • William Sellers, MD
    Vice President and Global Head of Oncology, Novartis Institutes for BioMedical Research

Fireside Chat: Joseph Jimenez, CEO, Novartis

  • Gregg Meyer, MD
    Chief Clinical Officer, Partners HealthCare
  • Joseph Jimenez
    CEO, Novartis

Cancer Diagnostics: New Uses, New Reimbursements?

  • Jeffrey Golden, MD
    Chair of Pathology, Brigham and Women’s Hospital
    Ramzi S. Cotran Professor of Pathology, Harvard Medical School
  • Helmy Eltoukhy, PhD
    CEO, Guardant Health, Inc.
  • Marc Grodman, MD, CEO
    BioReference Laboratories
  • John Iafrate, MD, PhD
    Associate in Pathology, Medical Director, Center for Integrated Diagnostics, MGH
    Professor of Pathology, Harvard Medical School
  • Neal Lindeman, MD
    Associate Pathologist, BWH
    Associate Professor, Pathology, Harvard Medical School
  • Michael Pellini, MD
    CEO, Foundation Medicine
  • Risa Stack, PhD
    General Manager, New Business Creation, GE Ventures

New Philanthropy: Patients Driving Innovation

  • Scott Sperling
    Co-President Thomas H. Lee Partners
  • Mallika Marshall, MD
    Health Reporter, WBZ-TV/CBS Boston
  • Louis DeGennaro, PhD
    President and CEO, The Leukemia & Lymphoma Society
  • Judy Salerno, MD
    President and CEO, Susan G. Komen for the Cure
  • Billy Starr
    Founder and Executive Director, Pan-Mass Challenge

Disruptive Dozen

  • Monica Bertagnolli, MD
    Chief, Division of Surgical Oncology, BWH
    Professor of Surgery, Harvard Medical School
  • Daniel Haber, MD, PhD
    Director, MGH Cancer Center, Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology, Harvard Medical School

Forum Closing

  • Anne Klibanski, MD
    Chief Academic Officer, Partners HealthCare
    Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Sponsors

Stakeholder

Boston Scientific logo

Strategic

amgen
Lilly footer
ge
Pfizer footer

Collaborators

Astra Zeneca - Footer
Bayer - Footer
CR Bard
Edwards footer
Mintz Levin footer
Novo Nordisk